Galectin-3 in heart failure with preservedejection fraction. A RELAX trial substudy (phosphodiesterase-5 inhibition to improve clinical status and exercise capacity in diastolic heartfailure).

JACC: Heart Failure

Volumn 3, Issue 3, 2015, Pages 245-252

  AbouEzzeddine, Omar F ^a   Haines, Phillip ^b   Stevens, Susanna ^c   Nativi Nicolau, Jose ^d   Felker, G Michael ^e   Borlaug, Barry A ^a   Chen, Horng H ^a   Tracy, Russell P ^f   Braunwald, Eugene ^g   Redfield, Margaret M ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF UTAH   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF VERMONT   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Biomarkers; Diastole; Galectin 3; Heart failure

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CARBOXY TERMINAL TELOPEPTIDE; CREATININE; CYSTATIN C; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; GALECTIN 3; HEMOGLOBIN; LOOP DIURETIC AGENT; SILDENAFIL; TROPONIN I; URIC ACID; PHOSPHODIESTERASE V INHIBITOR;

ADULT; AGE; AGED; ARTICLE; BODY SIZE; BREATHING DISORDER; CARDIOVASCULAR MAGNETIC RESONANCE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; ECHOCARDIOGRAPHY; EXERCISE TEST; FEMALE; FIBROSIS; HEART EJECTION FRACTION; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE VOLUME; HEART MUSCLE NECROSIS; HEART RATE; HUMAN; INFLAMMATION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; ORTHOPNEA; OXYGEN CONSUMPTION; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY ARTERY; QUALITY OF LIFE; RESPIRATORY EXCHANGE RATIO; RESPIRATORY TRACT PARAMETERS; SEX; SIX MINUTE WALK DISTANCE; SYSTOLIC BLOOD PRESSURE; VENTILATORY EFFICIENCY; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; EXERCISE TOLERANCE; HEART FAILURE, DIASTOLIC; HEART STROKE VOLUME; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

AGED; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXERCISE TOLERANCE; FEMALE; GALECTIN 3; HEART FAILURE, DIASTOLIC; HUMANS; MALE; MIDDLE AGED; PHOSPHODIESTERASE 5 INHIBITORS; QUALITY OF LIFE; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT;

EID: 84924912803     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2014.10.009     Document Type: Article

References (32)

1. Owan T.E., Hodge D.O., Herges R.M., Jacobsen S.J., Roger V.L., Redfield M.M. Trends in prevalence and outcome of heart failure with preserved ejection fraction. NEngl J Med 2006, 355:251-259.
2. Paulus W.J., Tschope C. Anovel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. JAm Coll Cardiol 2013, 62:263-271.
3. de Boer R.A., Voors A.A., Muntendam P., van Gilst W.H., van Veldhuisen D.J. Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail 2009, 11:811-817.
4. Sharma U.C., Pokharel S., van Brakel T.J., et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004, 110:3121-3128.
5. Liu Y.H., D'Ambrosio M., Liao T.D., et al. N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, amammalian adhesion/growth-regulatory lectin. Am J Physiol Heart Circ Physiol 2009, 296:H404-H412.
6. Yu L., Ruifrok W.P., Meissner M., et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail 2013, 6:107-117.
7. Schroen B., Heymans S., Sharma U., et al. Thrombospondin-2 is essential for myocardial matrix integrity: increased expression identifies failure-prone cardiac hypertrophy. Circ Res 2004, 95:515-522.
8. Calvier L., Miana M., Reboul P., et al. Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler Thromb Vasc Biol 2013, 33:67-75.
9. Januzzi J.L., Felker G.M. Surfing the biomarker tsunami at JACC: heart failure. JAm Coll Cardiol HF 2013, 1:213-215.
10. Ahmad T., Fiuzat M., Pencina M.J., et al. Charting a roadmap for heart failure biomarker studies. JAm Coll Cardiol HF 2014, 2:477-488.
11. Ho J.E., Liu C., Lyass A., et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure inthe community. JAm Coll Cardiol 2012, 60:1249-1256.
12. de Boer R.A., van Veldhuisen D.J., Gansevoort R.T., et al. The fibrosis marker galectin-3 and outcome in the general population. JIntern Med 2012, 272:55-64.
13. Felker G.M., Fiuzat M., Shaw L.K., et al. Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. Circ Heart Fail 2012, 5:72-78.
14. Lok D., Bruggink P., van der Meer P. Prognostic value of galectin-3, a novel marker of fibrosis. Clin Res Cardiol 2010, 99:529.
15. Tang W.H., Shrestha K., Shao Z., et al. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am J Cardiol 2011, 108:385-390.
16. Gopal D.M., Kommineni M., Ayalon N., et al. Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure. JAm Heart Assoc 2012, 1:e000760.
17. Anand I.S., Rector T.S., Kuskowski M., Adourian A., Muntendam P., Cohn J.N. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT. Eur J Heart Fail 2013, 15:511-518.
18. Lopez-Andrès N., Rossignol P., Iraqi W., et al. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. Eur J Heart Fail 2012, 14:74-81.
19. de Boer R.A., Lok D.J., Jaarsma T., et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 2011, 43:60-68.
20. van Kimmenade R.R., Januzzi J.L., Ellinor P.T., et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. JAm Coll Cardiol 2006, 48:1217-1224.
21. Ueland T., Aukrust P., Broch K., et al. Galectin-3 in heart failure: high levels are associated with all-cause mortality. Int J Cardiol 2011, 150:361-364.
22. Gullestad L., Ueland T., Kjekshus J., et al. Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Eur Heart J 2012, 33:2290-2296.
23. Forfia P.R., Borlaug B.A. Letter by Forfia and Borlaug regarding article, "Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study". Circulation 2012, 125:e408. author reply e9-10.
24. Redfield M.M., Chen H.H., Borlaug B.A., et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 2013, 309:1268-1277.
25. Redfield M.M., Borlaug B.A., Lewis G.D., et al. PhosphdiesteRasE-5 Inhibition to Improve CLinical Status and EXercise Capacity in Diastolic Heart Failure (RELAX) trial: rationale and design. Circ Heart Fail 2012, 5:653-659.
26. Stevens L.A., Coresh J., Schmid C.H., et al. Estimating GFR using serum cystatin C alone and incombination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis 2008, 51:395-406.
27. van der Velde A.R., Gullestad L., Ueland T., et al. Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. Circ Heart Fail 2013, 6:219-226.
28. Erkilet G., Ozpeker C., Bothig D., et al. The biomarker plasma galectin-3 in advanced heart failure and survival with mechanical circulatory support devices. JHeart Lung Transplant 2013, 32:221-230.
29. Beiras-Fernandez A., Weis F., Rothkopf J., et al. Local expression of myocardial galectin-3 does not correlate with its serum levels in patients undergoing heart transplantation. Ann Transplant 2013, 18:643-650.
30. Milting H., Ellinghaus P., Seewald M., et al. Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices. JHeart Lung Transplant 2008, 27:589-596.
31. Shah R.V., Chen-Tournoux A.A., Picard M.H., van Kimmenade R.R., Januzzi J.L. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail 2010, 12:826-832.
32. Cleland J.G., McMurray J.J., Kjekshus J., et al. Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). JAm Coll Cardiol 2009, 54:1850-1859.